• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      VENCLYXTO® (venetoclax) in Acute Myeloid Leukaemia (AML)

       

      In combination with a hypomethylating agent for newly-diagnosed patients with AML who are ineligible for intensive chemotherapy1

       

       

       

      UK-VNCAML-220109 | April 2022
      1. Venclyxto Summary of Product Characteristics

      Video library

      Haematology experts provide their opinions on key topics in the treatment of AML

      VIALE-A: Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

      Dr. Richard Dillon provides an overview of the VIALE-A trial of azacitidine and venetoclax in previously untreated acute myeloid leukemia patients who were ineligible for intensive chemotherapy

      Management strategies and real-world experience with venetoclax in first-line AML

      Watch Dr. Richard Dillion discuss his  experience using venetoclax in clinical practice and how he manages venetoclax treatment in first-line AML

      Expert opinion: Using venetoclax in first-line chemotherapy-ineligible AML

      Watch Professor Nigel Russel discuss venetoclax treatment in first-line AML patients ineligible for intensive chemotherapy

       

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com

      UK-VNCAML-220118. Date of preparation: April 2022.